Trial · NCT02121756
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12 | ARM A: Dipyridamole for 24 Weeks | 244500.00 | Inter-Quartile Range -318792.00 to 479000.00 | pg/ml | |
| Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD14 From Baseline to Week 12 | ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | -58250.00 | Inter-Quartile Range -572567.50 to 287500.00 | pg/ml | |
| Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12 | ARM A: Dipyridamole for 24 Weeks | -6.19 | Inter-Quartile Range -78.04 to 25.93 | ng/ml | |
| Monocyte and Macrophage Activation Assessed as Change in Plasma Levels of sCD163 From Baseline to Week 12 | ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | 5.42 | Inter-Quartile Range -38.33 to 88.33 | ng/ml | |
| Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12 | ARM A: Dipyridamole for 24 Weeks | -0.02 | Inter-Quartile Range -0.36 to 0.86 | pg/ml | |
| Systemic Inflammation Assessed as Change in IL-6 Plasma Levels From Baseline to Week 12 | ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | -0.07 | Inter-Quartile Range -0.59 to 0.88 | pg/ml | |
| Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | ARM A: Dipyridamole for 24 Weeks | -0.05 | Inter-Quartile Range -0.15 to 0.00 | proportion of CD8+ T cells | |
| Immune System Activation as Measured by the Proportion of CD8+ T Cells Co-expressing CD69 and CD25 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | 0.00 | Inter-Quartile Range -0.05 to 0.05 | proportion of CD8+ T cells | |
| Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | ARM A: Dipyridamole for 24 Weeks | Grade 2 adverse events | 12 | Participants | |
| Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Grade 2 adverse events | 10 | Participants | |
| Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | ARM A: Dipyridamole for 24 Weeks | Grade 3 adverse events | 2 | Participants | |
| Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Grade 3 adverse events | 1 | Participants | |
| Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | ARM A: Dipyridamole for 24 Weeks | Treatment discontinuations | 4 | Participants | |
| Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | Treatment discontinuations | 0 | Participants | |
| Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | ARM A: Dipyridamole for 24 Weeks | No Grade 2 or 3 AEs or treatment discontinuations | 3 | Participants | |
| Safety and Tolerability of Dipyridamole Assessed as the Number of Participants With Grade 2 or Higher Adverse Events or Treatment Discontinuations | ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | No Grade 2 or 3 AEs or treatment discontinuations | 8 | Participants | |
| Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole | ARM A: Dipyridamole for 24 Weeks | -0.15 | Inter-Quartile Range -0.30 to -0.05 | proportion of cycling CD4+ T Cells | |
| Immune System Activation Assessed as the Change in the Proportion of Cycling CD4+ T Cells as Measured by Ki-67 Expression at Baseline and After Treatment With Dipyridamole | ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | -0.05 | Inter-Quartile Range -0.20 to 0.05 | proportion of cycling CD4+ T Cells | |
| Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | ARM A: Dipyridamole for 24 Weeks | -0.25 | Inter-Quartile Range -0.70 to 0.00 | proportion of CD4+ T cells | |
| Immune System Activation as Measured by the Proportion of CD4+ T Cells Co-expressing HLA-DR and CD38 After 12 Weeks of Dipyridamole Treatment Compared to Placebo | ARM B: Placebo for 12 Weeks Then Dipyridamole for 12 Weeks | 0.10 | Inter-Quartile Range -0.65 to 0.55 | proportion of CD4+ T cells |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02121756/results